FDA-approved generic pergolide reaches horses with PPID

CURRENT FULL VERSION: A new generic option has arrived for one of equine practice’s most familiar chronic endocrine diseases. Zygolide, a pergolide tablet from Dechra, was approved by the FDA for control of clinical signs associated with pituitary pars intermedia dysfunction, or PPID, in horses, becoming the first generic version of the long-established brand Prascend. FDA announced the approval on January 9, 2026, after granting it on December 19, 2025. (fda.gov)

That timing matters because pergolide has been the mainstay medical treatment for PPID for years, and Prascend has effectively defined the category since its approval in 2011. PPID is common in older horses and typically requires long-term, often lifelong, therapy, which means even modest changes in price, formulation, or ease of administration can have outsized effects on adherence at the barn level. The FDA’s abbreviated approval pathway for Zygolide rested on bioequivalence to Prascend rather than a full repeat of efficacy studies, which is standard for a generic animal drug application. (fda.gov)

In its approval materials, FDA said Zygolide contains 1 mg pergolide per tablet, is available by prescription only, and is labeled for oral administration at a starting dose of 2 mcg/kg once daily, adjustable to effect up to 4 mcg/kg daily. The Freedom of Information summary says the sponsor demonstrated bioequivalence in a four-period crossover blood-level study in 24 healthy horses. Dechra’s launch messaging has focused on practical differentiators rather than a new indication: peppermint flavoring, blister packaging, and a 360-degree, half-scored tablet intended to simplify dose adjustments. Alongside those product features, the company’s consumer-facing ads have leaned into an emotional quality-of-life message, using lines such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best so you can enjoy more happy moments together.” (fda.gov; The Horse Zyoglide Carousel 2026 ads)

Dechra is also leaning heavily on affordability. In its announcement, the company said the product should offer cost relief, particularly for horses needing higher pergolide doses. That point lines up with broader reporting on PPID management economics: one recent summary of AAEP 2025 coverage noted that cost remains a meaningful factor in willingness to continue pergolide therapy over time. While independent, real-world pricing will vary by pharmacy and dose, the arrival of a generic is likely to be welcomed in cases where monthly medication expense has been a barrier. The ad campaign’s emphasis on enjoying “more happy moments together” also suggests Dechra is trying to frame affordability and administration as part of preserving function and the horse-owner bond over the long term, not just reducing pharmacy spend. (thehorse.com)

There is not yet much independent expert commentary specifically on Zygolide, but the broader clinical perspective on pergolide is well established. The Horse has previously reported that pergolide remains the only FDA-approved treatment class for PPID and that the goal of therapy is to reduce clinical signs and improve quality of life, while monitoring treatment response over time. More recent reporting has also pointed to generally favorable long-term pet parent satisfaction with pergolide treatment, though not without attention to cost and dose titration challenges. In that context, Dechra’s branding is notable because it mirrors how many veterinarians already discuss PPID management with clients: less as a cure than as a way to help older horses stay comfortable, functional, and engaged in daily routines. (thehorse.com)

Why it matters: For equine veterinarians, Zygolide’s significance is less about changing the standard of care than about widening access to it. A generic pergolide could help practices keep more PPID horses on consistent therapy, especially senior horses needing chronic treatment or higher doses. It may also support more precise dose tailoring if the tablet’s scoring proves useful in day-to-day administration. At the same time, clinicians will still need to set expectations around monitoring and safety: decreased appetite is a known issue with pergolide, and the label warns against crushing tablets because of human exposure concerns, with added caution for pregnant or lactating women handling the drug. The owner-directed marketing around partnership and “happy moments together” may resonate with clients, but it also gives practices an opening to connect adherence conversations to concrete goals such as comfort, body condition, attitude, and manageable daily care. (fda.gov)

Another practical consideration is competition and sport-horse management. Pergolide has long been clinically important enough that equestrian regulators created therapeutic use pathways for affected horses, underscoring how central the drug is in maintaining function and welfare in older performance horses. A more accessible generic could therefore have implications beyond routine medical management, including continuity of care for horses still in work. (aaevt.org)

What to watch: The next signal for the market will be whether pharmacies and equine practices report meaningful price separation from Prascend, and whether that translates into better refill persistence, fewer skipped doses, or earlier treatment uptake in borderline cost-sensitive cases. It will also be worth watching whether Dechra’s formulation features, especially flavoring and scoring, produce measurable adherence advantages in real-world use, and whether its horse-owner-focused campaign messaging helps drive awareness and acceptance of the new generic. (thehorse.com)